Literature DB >> 25378985

Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.

Jeong Uk Lim1, In Sook Woo1, Yun Hwa Jung1, Jae Ho Byeon1, Chan Kwon Park2, Tae Jung Kim3, Hyo Rim Kim4.   

Abstract

Entities:  

Keywords:  Acquired resistance; Erlotinib; Neuroendocrine

Mesh：

Substances：

Year:  2014        PMID： 25378985      PMCID： PMC4219976          DOI： 10.3904/kjim.2014.29.6.830

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN： 1226-3303            Impact factor:   2.884


× No keyword cloud information.
  5 in total

1.  EGFR mutations in small-cell lung cancers in patients who have never smoked.

Authors:  Maureen F Zakowski; Marc Ladanyi; Mark G Kris
Journal:  N Engl J Med       Date:  2006-07-13       Impact factor: 91.245

2.  Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.

Authors:  Satoru Yanagisawa; Naoto Morikawa; Yuichiro Kimura; Yoko Nagano; Kazuhiro Murakami; Toshiharu Tabata
Journal:  Respirology       Date:  2012-11       Impact factor: 6.424

3.  Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.

Authors:  S Popat; A Wotherspoon; C M Nutting; D Gonzalez; A G Nicholson; M O'Brien
Journal:  Lung Cancer       Date:  2013-01-10       Impact factor: 5.705

4.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

Review 5.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

Authors:  Kadoaki Ohashi; Yosef E Maruvka; Franziska Michor; William Pao
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544
  5 in total
  9 in total

1.  Targeting ALK in Neuroendocrine Tumors of the Lung.

Authors:  Dilara Akhoundova; Martina Haberecker; Ralph Fritsch; Sylvia Höller; Michael K Kiessling; Markus Rechsteiner; Jan H Rüschoff; Alessandra Curioni-Fontecedro
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

Review 2.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

3.  MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.

Authors:  Amy S Farrell; Meghan Morrison Joly; Brittany L Allen-Petersen; Patrick J Worth; Christian Lanciault; David Sauer; Jason Link; Carl Pelz; Laura M Heiser; Jennifer P Morton; Nathiya Muthalagu; Megan T Hoffman; Sara L Manning; Erica D Pratt; Nicholas D Kendsersky; Nkolika Egbukichi; Taylor S Amery; Mary C Thoma; Zina P Jenny; Andrew D Rhim; Daniel J Murphy; Owen J Sansom; Howard C Crawford; Brett C Sheppard; Rosalie C Sears
Journal:  Nat Commun       Date:  2017-11-23       Impact factor: 14.919

Review 4.  Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.

Authors:  Fiorella Calabrese; Federica Pezzuto; Francesca Lunardi; Francesco Fortarezza; Sofia-Eleni Tzorakoleftheraki; Maria Vittoria Resi; Mariaenrica Tiné; Giulia Pasello; Paul Hofman
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

5.  Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases.

Authors:  Cai-Bao Jin; Ling Yang
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

6.  Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4.

Authors:  Lili Tian; Dachuan Shen; Xiaodong Li; Xiu Shan; Xiaoqi Wang; Qiu Yan; Jiwei Liu
Journal:  Oncotarget       Date:  2016-01-12

7.  Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.

Authors:  Ki-Eun Hwang; Young-Suk Kim; Jae-Wan Jung; Su-Jin Kwon; Do-Sim Park; Byong-Ki Cha; Seon-Hee Oh; Kwon-Ha Yoon; Eun-Taik Jeong; Hak-Ryul Kim
Journal:  Oncotarget       Date:  2015-10-06

8.  pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma.

Authors:  Nusrat J Epsi; Sukanya Panja; Sharon R Pine; Antonina Mitrofanova
Journal:  Commun Biol       Date:  2019-09-06

9.  Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease.

Authors:  Hanping Wang; Li Zhang; Xiaohua Shi; Xiaotong Zhang; Xiaoyan Si
Journal:  Onco Targets Ther       Date:  2019-07-10       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.